Roche Paid $190 Million Up Front on a $2.3 Billion Headline for a Phase 1 Obesity Asset
- Hanmi Pharm licensed HM17321 to Genentech, part of the Roche Group, on 24 August 2026 for development, manufacture and commercialisation worldwide except South Korea. Hanmi receives $190 million up front, with development, regulatory and commercial milestones taking total potential value to roughly $2.3 billion, plus tiered royalties on net sales.
- HM17321 is a proprietary urocortin-2 (UCN2) analogue with a non-incretin mechanism, positioned as potential first-in-class. The pitch is simultaneous weight loss and preservation of lean body mass, against GLP-1 incretins that deliver weight reduction alongside a loss of lean mass.
- The asset is in Phase 1. FDA cleared the IND in November 2025, and the ongoing study evaluates safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers and people with obesity. Efficacy evidence to date is preclinical, as monotherapy and in combination with GLP-1 therapies.
- Hanmi completes Phase 1. Genentech takes over development from Phase 2 onward. Being peptide-based, HM17321 is framed as a candidate for fixed-dose combination or combination regimens with incretins rather than only as a standalone.
Deal read
The headline number is the wrong one to look at. What Roche actually committed is the upfront and the handover point, and both say this is an option on a mechanism rather than a bet on a drug.
- The upfront is 8% of the announced value. $190 million against roughly $2.3 billion means over 92% sits behind development, regulatory and commercial milestones that mostly resolve years out. Read the upfront as the price of the option and the rest as a schedule of things that may never be paid.
- The handover point is the tell. Hanmi finishes Phase 1 and Genentech starts at Phase 2. Roche buys the mechanism now and sees first-in-human safety and pharmacodynamic data before committing its own development spend. Watch the Phase 1 readout, because that is the real decision gate.
- The thesis is lean mass, and there is no human data on it yet. Preservation of lean body mass is the acknowledged weakness of incretins and a crowded target. Everything supporting HM17321 there is preclinical. The release itself frames combination with GLP-1s as a use case, which suggests add-on rather than replacement.
Read the original source (Hanmi Pharm) →
AssetsHM17321